Lördag 31 Maj | 02:40:16 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-25 08:00 Bokslutskommuniké 2025
2025-11-12 08:00 Kvartalsrapport 2025-Q3
2025-08-13 08:00 Kvartalsrapport 2025-Q2
2025-05-15 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2025-05-14 - Årsstämma
2025-05-14 - Kvartalsrapport 2025-Q1
2025-02-26 - Bokslutskommuniké 2024
2025-01-20 - Extra Bolagsstämma 2025
2024-11-13 - Kvartalsrapport 2024-Q3
2024-08-14 - Kvartalsrapport 2024-Q2
2024-05-30 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2024-05-29 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-04-05 - Extra Bolagsstämma 2024
2024-02-28 - Bokslutskommuniké 2023
2023-12-20 - Extra Bolagsstämma 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-07-24 - Kvartalsrapport 2023-Q2
2023-05-29 - Årsstämma
2023-05-16 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2023-05-08 - Kvartalsrapport 2023-Q1
2023-02-15 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-16 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2022-05-13 - Årsstämma
2022-05-13 - Kvartalsrapport 2022-Q1
2022-04-08 - Extra Bolagsstämma 2022
2022-02-16 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2021-05-07 - Årsstämma
2021-05-07 - Kvartalsrapport 2021-Q1
2021-02-16 - Bokslutskommuniké 2020
2020-11-10 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-06-05 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2020-06-04 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-14 - Bokslutskommuniké 2019
2019-12-19 - Extra Bolagsstämma 2019
2019-11-05 - Kvartalsrapport 2019-Q3
2019-08-13 - Kvartalsrapport 2019-Q2
2019-05-09 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2019-05-08 - Årsstämma
2019-05-08 - Kvartalsrapport 2019-Q1
2019-02-12 - Bokslutskommuniké 2018
2018-11-20 - Kvartalsrapport 2018-Q3
2018-08-21 - Kvartalsrapport 2018-Q2
2018-07-25 - Extra Bolagsstämma 2018
2018-05-09 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2018-05-08 - Årsstämma
2018-05-08 - Kvartalsrapport 2018-Q1
2018-02-20 - Bokslutskommuniké 2017
2017-11-21 - Kvartalsrapport 2017-Q3
2017-08-22 - Kvartalsrapport 2017-Q2
2017-05-11 - Årsstämma
2017-05-11 - Kvartalsrapport 2017-Q1
2017-04-22 - Bokslutskommuniké 2016
2016-11-11 - Kvartalsrapport 2016-Q3
2016-09-21 - Extra Bolagsstämma 2016
2016-08-24 - Kvartalsrapport 2016-Q2
2016-05-18 - Kvartalsrapport 2016-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHandel & varor
IndustriDagligvaror
Simris Group är ett bioteknikbolag. Bolaget är inriktat mot forskning och utveckling samt tillverkning av bioaktiva ämnen från odlade mikroalger, för tillämpningar inom nutrition, cosmeceuticals och läkemedel. Bolagets teknik ersätter även ohållbara råvaror från hotade arter och känsliga marina ekosystem. Första produkten är omega-3-tillskott som säljs under eget varumärke. Simris Group grundades 2011 och har sitt huvudkontor i Hammenhög.
2025-05-28 17:10:00

Simris Group AB (publ), reg. no. 556841–9187 (the "Company"), held its annual general meeting on 28 May 2025. Below follows a summary of the resolutions that were passed at the general meeting.

Income statements and balance sheets, disposition of the Company’s profit or loss and discharge from liability
The general meeting resolved to adopt the income statement and balance sheet for the fiscal year 2024 as presented in the annual report. Furthermore, the general meeting resolved, in accordance with the board of directors' proposal, that no dividend shall be paid and that the amount available at the general meeting's disposal should be carried forward to a new account.
 
Additionally, the general meeting resolved to grant discharge from liability to the board members and the managing director for their administration of the Company's affairs during the previous fiscal year.
 
Determination of fees for the board and auditors
The general meeting resolved that remuneration to non-employed board members elected by a general meeting shall be paid in the amount of SEK 140,000 to the chairman of the board and SEK 70,000 to each of the other board members. For any additional work in addition to customary board work, board members shall be able to receive consulting fees on market terms.
 
The general meeting resolved that fees to the Company’s auditor shall be paid according to approved invoices in accordance with customary charging principles.
 
Election of the board of directors and auditors
The general meeting resolved that the board shall consist of five (5) members without deputies. Furthermore, the general meeting resolved to re-elect Jonathan Royce, Magnus Högström and Frank Puccio as board members and to elect Richard Todd and Hadrien Forterre as new members of the board.
 
Richard Todd holds a Master of Science in Immunology and a Master of Business Administration from Imperial College and the University of Birmingham. Richard currently serves as a Process Development and Digital Training Fellow at the University of Birmingham.
 
Hadrien Forterre holds a Master of Laws from University Paris Nanterre and Duke University, and a Master of Business Administration from Columbia University. Hadrien currently also serves as vice president and general counsel at Pathify.
 
The general meeting also resolved that the Company shall have an authorised public accounting firm without deputies and to re-elect the Company's auditor Ernst & Young AB. Ernst & Young has announced that Peter Gunnarsson will continue as auditor in charge.
 
Amendment of the articles of association
The general meeting resolved to increase the Company's permitted minimum share capital from SEK 3,000,000 to SEK 5,500,000 and to increase the Company’s permitted maximum share capital from SEK 12,000,000 to SEK 22,000,000 by amending § 4 of the articles of association.
 
The general meeting further resolved to increase the permitted minimum number of shares in the Company from 340,000,000 shares to 625,000,000 shares and to increase the permitted maximum number of shares in the Company from 1,360,000,000 shares to 2,500,000,000 shares by amending § 5 of the articles of association.
 
Authorisation for the board to decide on issue of shares, convertibles and/or warrants
The general meeting resolved to authorise the board of directors to, on one or more occasions, during the period until the next annual general meeting, decide to increase the Company’s share capital. The increase in the share capital may take place through a new issue of series B shares and/or convertibles and/or warrants that entitles the conversion or new subscription of series B shares. The board of directors shall be able to decide on such an issue with a deviation from the shareholders’ preferential rights and/or with provision for cash payment or payment in kind or set-off. Issuance in accordance with this authorisation must take place at the market subscription price. The board of directors shall have the right to determine the conditions in general for the issue in accordance with this authorisation and who shall have the right to subscribe for new shares, convertibles and/or warrants.
 
Resolution to extend loan agreements
The general meeting resolved, in accordance with the board of directors’ proposal, to extend the loan agreements entered into with Frank Puccio amounting to EUR 50,000, Royce CoLabs AB, a company controlled by Jonathan Royce, amounting to EUR 10,000, Magnus Högström amounting to EUR 30,000, Arminnovate Ltd, a company controlled by Dr Alexis Roberts-McIntosh, amounting to EUR 20,000 and Christoffer Tell AB, a company controlled by Christoffer Tell, amounting to EUR 30,000 for a total loan amount of EUR 140,000 and to authorise the board of directors to execute the extension of the loan agreements until 31 March 2026.